Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field
Cipla stock trades at ₹1,388, down 0.48% or ₹6.70 from its previous close of ₹1,394.70
Cipla's shares dipped slightly on Friday as the company announced a partnership with China's Qilu Pharmaceutical to license and commercialize a biosimilar of Keytruda (pembrolizumab) in the United States. The stock closed at ₹1,388, down 0.48% from the previous close of ₹1,394.70. The deal strengthens Cipla's oncology and biosimilars portfolio, but Morgan Stanley warns of a crowded market with 13 other pembrolizumab biosimilars in development.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Morgan Stanley takes aim at X accounts posting its research businesstimes.com.sg
- Morgan Stanley takes aim at X accounts posting its research straitstimes.com
- Morgan Stanley abre la puerta a la corrección en Repsol expansion.com
